Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

about

Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials.

P2860

Q52640387-08854B7A-0019-4E3B-9E90-1DBD6D839EC1

P2860

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

Item

http://www.wikidata.org/entity/Q38892631

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Use of the Total Cancer Care S ...... Study to Evaluate Feasibility.

@en

type

Item

label

Use of the Total Cancer Care S ...... Study to Evaluate Feasibility.

@en

prefLabel

Use of the Total Cancer Care S ...... Study to Evaluate Feasibility.

@en

P1476

Use of the Total Cancer Care S ...... Study to Evaluate Feasibility.

@en

P2093

Anders Berglund

http://www.w3.org/2001/XMLSchema#string

Bin Li

http://www.w3.org/2001/XMLSchema#string

Daniel Sullivan

http://www.w3.org/2001/XMLSchema#string

David Fenstermacher

http://www.w3.org/2001/XMLSchema#string

Hadi Danaee

http://www.w3.org/2001/XMLSchema#string

Hongyue Dai

http://www.w3.org/2001/XMLSchema#string

Melissa Mitchell

http://www.w3.org/2001/XMLSchema#string

Steven A Eschrich

http://www.w3.org/2001/XMLSchema#string

William L Trepicchio

http://www.w3.org/2001/XMLSchema#string

William S Dalton

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: A value of information analysis.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

CD30 expression in follicular lymphoma.

A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.

Designing transformative clinical trials in the cancer genome era.

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

P304

e45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2196/RESPROT.7289

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28320689

http://www.w3.org/2001/XMLSchema#string

P932

5379017

http://www.w3.org/2001/XMLSchema#string

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

about

P2860

P2860

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932